Nextcure

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BELTSVILLE, Md., July 06, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the initiation of a Phase 1/2 clinical trial for NC762, a humanized B7-H4 monoclonal antibody.

NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors

NextCure Inc (NASDAQ: NXTC) has published preclinical data for NC410 in the online journal eLife. NC410 is currently being evaluated in a Phase 1/2 trial in patients with advanced or metastatic solid tumors.

NextCure's Immunomedicine NC410 Shows Promising Anti-Cancer Activity In Preclinical Studies

BELTSVILLE, Md., June 21, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of preclinical data in the online journal eLife establishing NC410 as a novel immunomedicine targeting immune-excluded regions of collagen-rich tumors and enabling normalization of the tumor immune microenvironment. NC410, currently being evaluated in a Phase 1/2 clinical trial in patients with advanced or metastatic solid tumors, is a first-in-class immunomedicine designed to block immune suppression mediated by LAIR-1, an immunomodulatory receptor expressed on T cells and myeloid cells, including dendritic cells.

NextCure and Collaborators Publish Preclinical Data on Novel Immunomedicine NC410

BELTSVILLE, Md., May 19, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that clinical trial investigator, Martin Gutierrez, M.D., Director, Phase 1 Program and Co-Chair of Thoracic Oncology at Hackensack University Medical Center, will present a Trials in Progress poster for NC410 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

NextCure to Present Trials in Progress Poster for NC410 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

BELTSVILLE, Md., May 06, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported first quarter 2021 financial results and provided a business update.

NextCure Reports First Quarter 2021 Financial Results

BELTSVILLE, Md., May 05, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 12th at 2:00 pm Eastern time.

NextCure to Present at the BofA Securities 2021 Virtual Health Care Conference

BELTSVILLE, Md., April 28, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit on May 5th at 2:40 pm Eastern time.

NextCure to Present at the 7th Annual Truist Securities Life Sciences Summit

BELTSVILLE, Md., April 10, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today presented preclinical and investigational new drug (IND)-enabling data for NC762 at the American Association for Cancer Research (AACR) Annual Meeting 2021. NC762 is a humanized monoclonal antibody specific for B7-H4 and is being developed for the treatment of cancer.

NextCure Presents Preclinical Data for NC762 at American Association for Cancer Research (AACR) Annual Meeting 2021

BELTSVILLE, Md., April 07, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the 20th Annual Needham Virtual Healthcare Conference on April 13th at 12:45 pm Eastern time.

NextCure to Present at the 20th Annual Needham Virtual Healthcare Conference

BELTSVILLE, Md., March 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported fourth quarter and full year 2020 financial results and provided a business update.

NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

BELTSVILLE, Md., March 02, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will host a Virtual R&D Update Event at 5:00 p.m. ET on Thursday, March 4.

REMINDER: NextCure to Host Virtual R&D Update Event on March 4, 2021

BELTSVILLE, Md., Feb. 26, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will host a Virtual R&D Update Event at 5:00 p.m. ET on Thursday, March 4.

NextCure to Host Virtual R&D Update Event on March 4, 2021

Los Angeles, California--(Newsfile Corp. - February 11, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc. ("NextCure" or "the Company") (NASDAQ: NXTC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities in 2019, are encouraged to contact the firm immediately.If...

LONG-TERM INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $NXTC #NXTC--LONG-TERM SHAREHOLDER REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc.

LONG-TERM SHAREHOLDER REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc. and Encourages Investors with Losses to Contact the Firm

BELTSVILLE, Md., Jan. 14, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Dr. Han Myint, MD, FACP as chief medical officer. Dr. Myint will oversee the clinical development of key products in NextCure's product pipeline, including NC318, a first-in-class immunomedicine, targeting Siglec-15 (S15), and NC410, recombinant LAIR-2 fusion protein designed to block immune suppression mediated by the immune modulator LAIR-1. Prior to joining NextCure, Dr. Myint held senior roles at both Celgene (a Bristol Myers Squibb Company) and NexImmune Inc.

Dr. Han Myint Appointed as NextCure's Chief Medical Officer

Amarin Corporation Plc

Intercept Pharma

Invesco Mortgage Capital

NGL Energy Partners

PBF Energy

SNDL Inc.

Tricida Inc

Tellurian

Washington Prime Group

These companies are eager to say good riddance to the year that was.

The 10 Worst Performing Stocks of 2020

LOS ANGELES--(BUSINESS WIRE)---- $NXTC #NXTC--The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc. (“NextCure” or “the Company”) (NASDAQ: NXTC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities in 2019, are encouraged to contact the firm immediately. If you are a shareh

LONG-TERM SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc. and Encourages Investors with Losses to Contact the Firm

BELTSVILLE, Md., Dec. 17, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on the clinical trial program for NC318, its first-in-class immunomedicine against Siglec15 (S15), a novel immunomodulatory target.

NextCure Provides Updates on NC318 Clinical Program

NextCure (NXTC) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

NextCure (NXTC) in Focus: Stock Moves 7.6% Higher

NEW YORK, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NextCure (“NextCure” or the “Company”) (NASDAQ: NXTC).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NextCure, Inc. - NXTC

BELTSVILLE, Md., Nov. 23, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the Piper Sandler Virtual 32nd Annual Healthcare Conference on December 1st.

NextCure to Present at Piper Sandler Virtual 32nd Annual Healthcare Conference

NEW YORK, Nov. 20, 2020 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has been filed on behalf of investors that: (i) purchased or acquired the...

NXTC CLASS ACTION DEADLINE: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against NextCure Inc.

New York, New York--(Newsfile Corp. - November 19, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5, 2019 and July 14, 2020, inclusive (the "Class Period"); and/or (2) pursuant or traceable to NextCure's November 2019 secondary public offering of the important November 20, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for NextCure...

Final Deadline Alert: Rosen, Global Investor Counsel, Reminds NextCure, Inc. Investors of Important November 20 Deadline in Securities Class Action - NXTC

Los Angeles, California--(Newsfile Corp. - November 18, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc. (NASDAQ: NXTC) ("NextCure" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 5, 2019 and July 14, 2020,...

FRIDAY DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $NXTC #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming November 20, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired NextCure, Inc. (“NextCure” or the “Company”) (NASDAQ: NXTC) (a) securities between November 5, 2019 and July 14, 2020, inclusive (the “Class Period”); and/or (b) common stock pursuant or traceable to NextCure's November 2019 secondary public offering (“SPO” or the “Offering”). If

News for Nextcure Stock (NXTC)